In Part 1, I discussed some of the unfortunate events that led to Boston Scientific (BSX) falling from its once-lofty position alongside Medtronic (MDT), Johnson & Johnson (JNJ) and other major med-tech players. Through a mix of mismanagement, excessive appetite, and competitors' successes, Boston Scientific has found itself languishing for years.
Now, though, the company appears to be serious about change. Company-wide restructurings are underway, the company sold its once-promising neurovascular business to Stryker (SYK), and both management and investors await what they hope will be successful new product launches in the coming years. While all of this is taking place, though, there is a steady drumbeat in the rumor mill that Boston Scientific will not be independent for long.
In this section I mean to examine what the buyout environment for Boston Scientific could be like and who could be interested in this company.
Please continue on to Seeking Alpha for the full text:
http://seekingalpha.com/article/257222-boston-scientific-at-a-crossroads-the-case-for-bowing-out-part-2-of-2?source=mc_all
No comments:
Post a Comment